Overview
A number of viral health insurance products promising both protection and wealth management have been withdrawn from sale. According to Jiemian News, many took the form of individual-account long-term medical insurance, adding no-threshold medical cash accounts covering non-essential scenarios from outpatient and inpatient care to massage and cosmetic dentistry. Regulators view such designs as effectively circumventing pricing-rate constraints and the “consistency of prices and expenses” requirement.
Zhu Junsheng, a professor and postdoctoral fellow in applied economics at Peking University, says the withdrawals are superficially about marketing, sales and design, but the deeper cause is that individual-account long-term medical insurance remains in an exploratory phase of “policy encouragement, missing rules.” The financial regulator’s guiding opinions on high-quality health insurance development explicitly support such business, opening room for innovation; yet detailed business rules, product standards, account-management requirements, return-disclosure norms and risk-liability boundaries have not been issued, and insurers interpret product forms quite differently.
Regulators have launched a special rectification under the 2026 negative list for life insurance products, making clear such products may no longer be sold and that similar high-yield combination products will not be approved going forward.
Background & Interpretation
1. Regulatory and industry context
High-quality health insurance development has been a regulatory priority, with guiding opinions encouraging long-term, sustainable protection innovation — individual-account long-term medical insurance being one direction. At the same time, the regulator has used the product negative list, pricing-expense consistency and dynamic assumed-interest-rate adjustments to contain interest-spread losses. The withdrawals signal a “regulate first, develop later” sequence: before rules are complete, products that dilute protection with investment features will not be allowed to scale.
2. Core drivers and mechanisms
Problem products promise implied returns far above regulatory caps, eroding solvency and accumulating interest-spread risk over time. The mechanism is straightforward: insurers commit to relatively high long-term returns, but current asset-side yields may not fully cover them. If investments underperform, insurers must fill the gap with capital, directly hitting solvency ratios. Moreover, packaging “wealth first, protection second” as innovation makes the purchase driver capital appreciation rather than health coverage, departing from the product’s function and inviting mis-selling. With rules absent, interpretations of account management and return disclosure vary widely — making undesirable market practices hard to avoid.
3. Market structure and value-chain impact
The withdrawals leave a product gap in health insurance, which compliant long-term medical, critical-illness and inclusive products may fill. Competition is shifting from return comparisons back to coverage design and risk-control capability. Insurers must return to actuarial discipline in product design and pricing, adopt more prudent investment-return assumptions and strengthen asset-liability management. Distribution and consumers face tighter sales-script and benefit-illustration rules, narrowing the space for “high-yield health insurance” pitches. If rules are completed, individual-account medical cover may restart within a clearer framework, with stronger emphasis on protection and well-defined risk boundaries.
Implications & Outlook
Near term, withdrawals will reduce premium growth for some carriers and force a review of responsibilities and return illustrations in existing products. Medium-term variables include when business rules and product standards are issued, whether the negative list keeps updating, how dynamic interest-rate mechanisms interact with product innovation, and whether compliant products can meet genuine protection demand. Timely rules could create a positive cycle between innovation and regulation.
Takeaways for Industry Participants
Insurers should innovate within well-defined boundaries, prioritizing coverage design and health-management services over return illustrations. Distributors should standardize scripts and benefit disclosures, moving suitability reviews and risk warnings forward. Consumers should focus on coverage scope, exclusions and long-term claims-paying ability rather than “account growth” pitches. Observers should distinguish policy-encouraged directions from the preconditions for product implementation, avoiding the mistake of reading exploratory practices during a rule vacuum as a lasting trend.
This column compiles industry information and shares technical perspectives; it does not constitute investment advice.